Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. raised its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 59.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,014 shares of the medical research company's stock after acquiring an additional 5,609 shares during the quarter. Pittenger & Anderson Inc.'s holdings in Edwards Lifesciences were worth $1,111,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in EW. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC grew its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC increased its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on EW. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Truist Financial restated a "hold" rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research report on Monday, October 28th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and an average target price of $79.95.

Edwards Lifesciences Stock Down 2.0 %

NYSE:EW traded down $1.46 on Friday, reaching $73.25. The stock had a trading volume of 2,843,619 shares, compared to its average volume of 4,417,774. The company has a 50-day moving average of $72.85 and a 200 day moving average of $69.94. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $43.20 billion, a P/E ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,489 shares of company stock valued at $2,002,829. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.